Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (161-170 of 391) with videos related to

Pageof 40
Sort By:
The European Respiratory Journal|December 22, 2023
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosisMarlies Wijsenbeek, Jeffrey J Swigris, Yoshikazu Inoue, et al.
The Lancet. Respiratory Medicine|September 20, 2017
A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trialSurinder S Birring, Marlies S Wijsenbeek, Sanjay Agrawal, et al.
Respirology (Carlton, Vic.)|May 12, 2020
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort studyMark G Jones, Christopher R T Hillyar, Anjan Nibber, et al.
Clinical Reviews in Allergy & Immunology|March 18, 2022
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and ManagementElena De Zorzi, Paolo Spagnolo, Elisabetta Cocconcelli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2017
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic SclerosisNicole S Goh, Rachel K Hoyles, Christopher P Denton, et al.
Respiration; International Review of Thoracic Diseases|April 12, 2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received PirfenidoneMichael Kreuter, Paolo Spagnolo, Wim Wuyts, et al.
Annals of the American Thoracic Society|September 17, 2021
Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim AnalysisFasihul Khan, Lucy Howard, Glenn Hearson, et al.
The European Respiratory Journal|March 26, 2021
Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosisIain D Stewart, Henry Nanji, Grazziela Figueredo, et al.
BMJ Open Respiratory Research|September 1, 2018
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
The European Respiratory Journal|June 6, 2019
Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosisJoseph Barnett, Philip L Molyneaux, Bhavin Rawal, et al.
Pageof 40

Showing results (161-170 of 391) with videos related to

Sort By:
Pageof 40
The European Respiratory Journal|December 22, 2023
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosisMarlies Wijsenbeek, Jeffrey J Swigris, Yoshikazu Inoue, et al.
The Lancet. Respiratory Medicine|September 20, 2017
A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trialSurinder S Birring, Marlies S Wijsenbeek, Sanjay Agrawal, et al.
Respirology (Carlton, Vic.)|May 12, 2020
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort studyMark G Jones, Christopher R T Hillyar, Anjan Nibber, et al.
Clinical Reviews in Allergy & Immunology|March 18, 2022
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and ManagementElena De Zorzi, Paolo Spagnolo, Elisabetta Cocconcelli, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 21, 2017
Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic SclerosisNicole S Goh, Rachel K Hoyles, Christopher P Denton, et al.
Respiration; International Review of Thoracic Diseases|April 12, 2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received PirfenidoneMichael Kreuter, Paolo Spagnolo, Wim Wuyts, et al.
Annals of the American Thoracic Society|September 17, 2021
Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim AnalysisFasihul Khan, Lucy Howard, Glenn Hearson, et al.
The European Respiratory Journal|March 26, 2021
Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosisIain D Stewart, Henry Nanji, Grazziela Figueredo, et al.
BMJ Open Respiratory Research|September 1, 2018
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
The European Respiratory Journal|June 6, 2019
Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosisJoseph Barnett, Philip L Molyneaux, Bhavin Rawal, et al.
Pageof 40